NCT00596206已完成3 期
Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 124
- 试验地点
- 1
- 主要终点
- Clinical efficacy response rate using ACR 20 criteria in each initial dosing regimen group
研究概览
简要总结
To assess the efficacy response rate at 3-months of two dosing regimen of leflunomide in DMARDs-naive patients presenting an early-RA using American College of Rheumatology 20% response rate.
To assess the clinical efficacy at 1-month and 3-month using complementary efficacy criteria (ACR 50, ACR 70, DAS 28) in each group of treatment, To assess the clinical and biological safety using standard blood monitoring, TEAED and SAE in each group of treatment, To evaluate treatment modifications; particularity leflunomide and concomitant use of AINS and corticoids.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of active rheumatoid arthritis in the previous 6 months (according to the ACR guidelines)
- •Must have active disease to be initiated by DMARDs (Disease Modifying Anti-Rheumatic Drugs)
排除标准
- •Patient presenting or having a history of other inflammatory joint disease
- •Patient with ongoing or previous Stevens-Johnson syndrome, toxic epidermal necrolysis or erythema multiforme
- •Patient with significantly impaired bone marrow function or significant anaemia, leucopenia or thrombocytopenia due to causes or other than active rheumatoid arthritis
- •Persistent infection or severe infection within 3 months before enrollment,
- •Uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, terminal illness or other medical condition which, in the opinion of the investigator, would put the patient at risk to participate in the study,
- •Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
- •Severe hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin < 3.0 g/dl
- •Moderate or severe impairment of renal function, as known by serum creatinine > 133 mcmol/L (or 1.5 mg/dl)
- •Patient with history of recent and clinically significant drug or alcohol abuse
- •Impairment of liver function or persisting ALT (SGPT) elevations of more than 2-fold the upper limit of normal
- •Pregnancy
- •Breastfeeding
- •Women of childbearing potential, except if they fulfill specific conditions,
- •Men wishing to father children during the course of the study or within the 24 months thereafter (or 3 month with the washout procedure)
- •Patient with a congenital or acquired severe immuno-deficiency, a history of cancer or lymphoproliferative disease, or any patient who has received total lymphoid irradiation
- •Known HIV positive status
- •Known positive serology for hepatitis B or C
- •Patient with hypersensitivity to any of the excipients in the tablets of leflunomide
- •Previous therapy at any time with:
- •any DMARD including methotrexate, oral or injectable gold salts, chloroquine, hydroxychloroquine, ciclosporin, azathioprine, methotrexate, sulfasalazine
- •D penicillamine
- •alkylating agents, e.g., cyclophosphamide, chlorambucil, biological agents, e.g., interferon, monoclonal antibodies, growth factor, cytokines
- •any investigational drug
- •any antimetabolites
- •any opiates
- •Therapy within the previous 4 weeks with:
- •oral corticosteroids exceeding a prednisolone equivalent of 10 mg/day
- •parenteral or intra-articular corticoid injection
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Experimental
100 mg of leflunomide
干预措施: leflunomide (Drug)
2
Active Comparator
20 mg of leflunomide
干预措施: leflunomide (Drug)
结局指标
主要结局
Clinical efficacy response rate using ACR 20 criteria in each initial dosing regimen group
时间窗: at 3 month
次要结局
- Clinical efficacy response rate using ACR 50, ACR 70, DAS 28 efficacy criteria in each group of treatment(at 1 and 3 months)
- Clinical and biological safety using standard blood monitoring, TEAED and SAE in each group of treatment(From the Informed Consent Form (ICF) signature to the end of the study)
- Measure of acute phase response (ESR, CRP)(At 1 and 3 months)
- Patient and physician global assessment(At 1 and 3 months)
- SF-36 questionnaire(At 1 and 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic ApproachesRheumatoid ArthritisNCT04022525Assiut University80
招募中
2 期
eflunomide for musculoskeletal GVHD after allogeneic stem cell transplantCTRI/2021/04/033214Dr Sachin Punatar
终止
2 期
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukaemiaNCT00751296University Health Network, Toronto27
已完成
1 期
Leflunomide in Treating Patients With Relapsed or Refractory Multiple MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT02509052City of Hope Medical Center12
招募中
2 期
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine TumorNeuroendocrine TumorsNCT06540937Cancer Institute and Hospital, Chinese Academy of Medical Sciences50